05/04/23 4:30 PMNasdaq : AXLA earningsAxcella Reports First Quarter Financial Results and Provides Business UpdateAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “Patients are seeking a Long COVID therapy, as we have seen...RHEA-AIneutral
04/17/23 8:00 AMNasdaq : AXLA covid-19Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced two oral presentations of results from the Phase 2 a clinical trial of AXA1125 in the treatment of Long COVID Fatigue at the European Congress of...RHEA-AIneutral
03/30/23 8:00 AMNasdaq : AXLA earningsAxcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “The year 2022 was one of significant...RHEA-AIneutral
02/15/23 4:10 PMNasdaq : AXLA covid-19Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID FatigueAxcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced its Investigational New Drug application to initiate a phase 2 b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been...RHEA-AIneutral
02/09/23 4:45 PMNasdaq : AXLA conferencesAxcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma ConferenceAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities’ 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023.RHEA-AIneutral
01/23/23 4:15 PMNasdaq : AXLA covid-19Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID FatigueAxcella will be meeting with the MHRA in the near term to discuss the Innovative Licensing and Access Pathway application. The company further reported submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for a Phase 2 b/3 trial. Recent estimates indicate that 15-20% of Americans with COVID have persisting health...RHEA-AIneutral
12/14/22 8:01 PMNasdaq : AXLA Axcella Announces Program Reprioritization and Corporate RestructuringAxcella Therapeutics, a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. “The strategic process we initiate today prioritizes...RHEA-AIpositive
11/03/22 9:59 AMNasdaq : AXLA conferencesAxcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual MeetingAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases...RHEA-AIneutral
11/01/22 7:00 AMNasdaq : AXLA earningsAxcella Reports Third Quarter Financial Results and Provides Business UpdateAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “This has been an extremely exciting period for Axcella,”...RHEA-AIneutral
10/27/22 8:30 AMNasdaq : AXLA conferencesearningsAxcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it plans to report its third quarter 2022 financial results and other business updates on November 1, 2022. The company will host a conference call at...RHEA-AIneutral